Loading…
INVICORP is a brand name for Phentolamine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Invicorp is indicated for the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Invicorp 25 micrograms / 2 mg. The injection should provide the patient with an erection that is satisfactory for sexual intercourse. It is recommended that the duration of the erection does not exceed one hour. Injection frequency should not exceed once daily or 3 times weekly.
Paediatric population:
Invicorp is not recommended in children.
Elderly:
No formal studies have been performed in patients above 75 years of age.
Impaired renal or hepatic function:
No formal studies have been performed in patients with impaired renal or hepatic function. 6). The intracavernosal injection must be done under sterile conditions. Invicorp should be administered by direct intracavernous injection. The usual site of injection is along the dorsolateral aspect of the proximal third of the penis.
Visible veins should be avoided. Both the side of the penis and the site of injection must be altered between injections. The initial injections of Invicorp must be administered by medically trained personnel, and after proper training, Invicorp may be injected at home.
g. every 3 months) particularly in the initial stages of self-injection therapy.
8. Invicorp must be used with caution in patients with severe cardiovascular or cerebrovascular conditions. Sexual stimulation and intercourse can lead to cardiac and pulmonary events in patients with coronary heart disease, congestive heart failure and pulmonary disease.
The potential risks in connection with intercourse in patients on multi- drug treatment for cardiovascular symptoms may be increased by the treatment itself or by the patient’s underlying heart disease. These patients when using Invicorp should engage in sexual activity with caution.
If tachycardia occurs, treatment with Invicorp should be discontinued. 5). The potential for abuse of Invicorp should be considered in patients with a history of psychiatric disorder or addiction. 2). 05 mmol sodium per dose which means it is essentially sodium-free.
5 Interaction with other medicinal products and other forms of interaction Invicorp should be used with caution in combination with anticoagulants such as heparins and warfarin, including oral anticoagulants such as dabigatran, rivaroxaban or apixaban.
No clinical interaction has been observed in the use of Invicorp with concomitant intake of anti-hypertensive or other cardiovascular medication. 6 Fertility, pregnancy and lactation Not relevant. Invicorp is only indicated in men. No reproduction studies have been carried out on animals using a combination of aviptadil and phentolamine mesilate.
The effect of concomitant treatment with Invicorp and other treatments for erectile dysfunction (eg sildenafil) or with other drugs that induce erection (eg papaverine) has not been formally studied. Such medicinal substances should not be used with Invicorp because of the potential for prolonged duration of erections.
7 Effects on ability to drive and use machines No trials on the effect on the ability to drive a car or use machines have been carried out. 8 Undesirable effects Approximately 10% of patients experience adverse reactions. Flushing is often observed but is rarely problematic and may be difficult to distinguish from the flushing associated with intercourse.
Underlying treatable medical causes of erectile dysfunction should be diagnosed and treated prior to initiation of therapy with Invicorp. 8). Patients should be instructed to immediately report to a physician any erection lasting for a prolonged period, such as 4 hours or longer.
Treatment of priapism should not be delayed more than 6 hours. 9). Penile fibrosis, including angulation, cavernosal fibrosis, fibrotic nodules and Peyronie's disease may occur following the intracavernosal administration of Invicorp.
8). Regular follow-up of patients, with careful examination of the penis, is strongly recommended to detect signs of penile fibrosis or Peyronie's disease. Whilst not so far observed onInvicorp, the attending doctor should be aware of the possibility of an association.
Treatment with Invicorp should be discontinued in patients who develop penile angulation, cavernosal fibrosis, or Peyronie's disease. 8). 8). In these cases patients may be withdrawn from treatment. 8. Invicorp must be used with caution in patients with severe cardiovascular or cerebrovascular conditions.
Sexual stimulation and intercourse can lead to cardiac and pulmonary events in patients with coronary heart disease, congestive heart failure and pulmonary disease. The potential risks in connection with intercourse in patients on multi- drug treatment for cardiovascular symptoms may be increased by the treatment itself or by the patient’s underlying heart disease.
These patients when using Invicorp should engage in sexual activity with caution. If tachycardia occurs, treatment with Invicorp should be discontinued. 5). The potential for abuse of Invicorp should be considered in patients with a history of psychiatric disorder or addiction.
2). 05 mmol sodium per dose which means it is essentially sodium-free.
1. Men for whom sexual activity is not advisable or is contraindicated due to organic disease. Men with either of the following should not be treated with Invicorp: • Conditions that might predispose to priapism, such as sickle cell anaemia or trait, multiple myeloma, or leukemia.
• Anatomical deformation of the penis, such as angulation, cavernosal fibrosis, or Peyronie’s disease. • Penile implants.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Phentolamine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Haematoma and bruise may occur at the injection site. This will become less of a problem when patients become more experienced in the injection technique itself. Nervous system disorders Uncommon (≥1/1,000 to <1/100) Headache, dizziness.
Cardiac disorders Uncommon (≥1/1,000 to <1/100) Very rare (<1/10,000) Tachycardia, palpitations. Myocardial infarction, angina pectoris. Vascular disorders Common (≥1/100 to <1/10) Flushing. Reproductive system and breast disorders Rare (≥1/10,000 to <1/1,000) Priapism, prolonged erection.
Penile nodules/fibrosis following multiple injections. General disorders and administration site conditions Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Rare (≥1/10,000 to <1/1,000) Bruising. Haematoma. Pain post injection. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard alternatively you can call Freephone 0808 100 3352 (available between 10am-2pm Monday-Friday) or fill in a paper form available from your local pharmacy.